Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM3 | Q14832 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5659416 | 0.87 | POLB (0.37) | ALDH1A1POLBEPHX2 | |
| SCHEMBL5660846 | 0.87 | DPP4 (0.42) | ALDH1A1POLBCNR2 | |
| SCHEMBL5656407 | 0.86 | GRM3 (0.38) | GRM3HPGDALDH1A1SMN1; SMN2POLB | |
| SCHEMBL5655978 | 0.85 | RECQL (0.38) | ALDH1A1POLBGAAEPHX2 | |
| SCHEMBL5659715 | 0.84 | MEN1 (0.39) | HPGDPOLBGAA | |
| SCHEMBL5657247 | 0.82 | ALDH1A1 (0.35) | ALDH1A1POLB | |
| SCHEMBL5659314 | 0.80 | CTSK (0.31) | — | |
| SCHEMBL5659925 | 0.80 | ALDH1A1 (0.48) | HPGDALDH1A1POLBLMNAGAA | |
| SCHEMBL5656721 | 0.80 | GRM3 (0.39) | GRM3 | |
| SCHEMBL5656403 | 0.78 | HPGD (0.41) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7192953-B2 | Antibacterial agents | VERNALIS (OXFORD) LIMITED (GB) | 2007-03-20 | — | — | US | disclosed |
| US-20060128811-A1 | Hydroxamic acid- and N-formyl hydroxylamine hydrazide derivatives; veterinary medicine | VERNALIS (OXFORD) LIMITED (GB) | 2006-06-15 | — | — | US | disclosed |
| EP-1567504-A1 | ANTIBACTERIAL AGENTS | Vernalis (Oxford) Ltd (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050638-A1 | ANTIBACTERIAL AGENTS | VERNALIS (OXFORD) LTD. (GB) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128811-A1 | Hydroxamic acid- and N-formyl hydroxylamine hydrazide derivatives; veterinary medicine | HRH2, HCAR3, HCAR2 | GRM3 970/4885HPGD 359/4885ALDH1A1 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.